Immunovant Inc (IMVT) is a Healthcare · Biotechnology company listed on NASDAQ. Price $36.95 (-1.86%), Market cap $7.30B, 52-week low–high $14.10 ~ $35.56.
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Financial statements, price targets, institutional (13F) holdings and related news for Immunovant Inc are updated in real time on BlackAll Trade.
Immunovant Inc trades at $36.95 (-1.86%). Real-time quotes and charts are available on BlackAll Trade.
Immunovant Inc has a market cap of about $7.30B.
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthe